How Prelude Therapeutics is advancing a JAK2 JH2 strategy into the clinic after FDA IND clearance
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.
Can CK0804 overcome JAK inhibitor resistance in myelofibrosis and reshape the Treg cell therapy landscape?
Cellenkos, Inc., a clinical-stage biotechnology company developing allogeneic regulatory T cell (Treg) therapies, has unveiled new data from its investigational product CK0804, presented at the 67th American Society of Hematology (ASH) Annual Meeting. The findings highlight the potential of a dose-intensive regimen of CK0804 to reduce spleen volume, improve symptoms, and lower transfusion dependence in […]